Rigel Pharmaceuticals (RIGL) Debt to Equity (2019 - 2026)
Rigel Pharmaceuticals (RIGL) recorded quarterly Debt to Equity of $0.19 in Q1 2026, up 39.88% quarter-over-quarter from $0.13 in Q4 2025, and down 94.19% on a YoY basis from $3.22 in Q1 2025.
Rigel Pharmaceuticals (RIGL) Debt to Equity (2019 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Debt to Equity history runs 8 years deep, the most recent figure standing at $0.19 for Q1 2026.
- In Q1 2026, Debt to Equity fell 94.19% year-over-year to $0.19; the TTM figure through Mar 2026 stood at $0.19 (down 94.19% YoY), while the FY2025 annual figure was $0.13, down 99.26% from the prior year.
- Debt to Equity was $0.19 for Q1 2026 at Rigel Pharmaceuticals, up from $0.13 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $18.15 in Q4 2024 to a low of -$8.11 in Q2 2022.
- Historically, Debt to Equity has averaged -$0.13 across 5 years, with a median of -$1.88 in 2024.
- Biggest YoY gain for Debt to Equity was 1632.37% in 2022; the steepest drop was 2882.69% in 2022.
- A 5-year view of Debt to Equity shows it stood at -$2.9 in 2022, then advanced by 28.18% to -$2.08 in 2023, then surged by 972.31% to $18.15 in 2024, then plunged by 99.26% to $0.13 in 2025, then surged by 39.88% to $0.19 in 2026.
- The last three Debt to Equity figures came in at $0.19 (Q1 2026), $0.13 (Q4 2025), and $0.51 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Rigel Pharmaceuticals | 603.18 Mn | 456.49 Mn | 54.21 Mn | 0.19 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.19 |
| Dec 31, 2025 | 0.13 |
| Sep 30, 2025 | 0.51 |
| Jun 30, 2025 | 0.73 |
| Mar 31, 2025 | 3.22 |
| Dec 31, 2024 | 18.15 |
| Sep 30, 2024 | -4.08 |
| Jun 30, 2024 | -2.00 |
| Mar 31, 2024 | -1.88 |
| Dec 31, 2023 | -2.08 |
| Sep 30, 2023 | -1.87 |
| Jun 30, 2023 | -2.12 |
| Mar 31, 2023 | -2.45 |
| Dec 31, 2022 | -2.90 |
| Sep 30, 2022 | -1.99 |
| Jun 30, 2022 | -8.11 |
| Mar 31, 2022 | 4.39 |
| Dec 31, 2021 | 0.66 |
| Sep 30, 2021 | 0.40 |
| Jun 30, 2021 | 0.29 |